Literature DB >> 33188871

Clinical characteristics and histopathologic changes of morphea: A single-center, retrospective study of 137 patients.

Jemin Kim1, Kyung Bae Chung1, Young In Lee1, Jihee Kim1, Ju Hee Lee2.   

Abstract

BACKGROUND: The clinicopathologic correlations and prognostic risk factors for refractory disease in morphea (localized scleroderma) are poorly described.
OBJECTIVE: To investigate the association between clinical characteristics and histopathologic features of morphea and identify risk factors for refractory disease.
METHODS: We retrospectively reviewed the clinical and histopathologic features, treatment regimens, and clinical responses for 137 patients with biopsy-proven morphea from January 2008 to May 2019. Multivariate analysis was conducted to identify factors associated with poor treatment response.
RESULTS: We detected associations between the pattern and degree of sclerosis and the anatomic site of the lesion, as well as between severe inflammation and concomitant autoimmune disease. Additionally, both bottom-heavy sclerosis and increased inflammation were associated with functional limitations/clinical symptoms. Based on our multivariate analysis, we found that increased risk of poor treatment response was correlated with tissue eosinophils and basal pigmentation. LIMITATIONS: This was a single-center retrospective study.
CONCLUSION: Skin biopsy samples could show specific features of morphea, including eosinophil infiltration and basal pigmentation, which may indicate the need for aggressive treatment and frequent monitoring.
Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  autoimmune disease; localized scleroderma; morphea; pathology; prognosis; sclerosis

Year:  2020        PMID: 33188871     DOI: 10.1016/j.jaad.2020.11.006

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  1 in total

1.  Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection.

Authors:  Zeinab Aryanian; Kamran Balighi; Parvaneh Hatami; Nasim Mazloumi Tootoonchi; Azadeh Goodarzi; Zeinab Mohseni Afshar
Journal:  Clin Case Rep       Date:  2022-04-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.